arginine vasopressin

[Deamino-4-valine, 8-D-arginine]-Vasopressin (dVDAVP) is a highly potent and specific antidiuretic agent with prolonged effects [1] [2].

Vasopressin (argipressin), a cyclic nine-peptide synthesized by hypothalamic neurons, is one of the hormones involved in peptide prohormone synthesis. Vasopressin is involved in the regulation process of hypothalamic-pituitary-adrenal axis, increasing the amount of solute free water reabsorbed from the renal tubule's colate back into the circulation, narrowing arteries to increase pressure, enhancing the stimulating effect of corticotropin releasing factor to regulate pituitary corticotropin secretion. Vasopressin acts as a neurotransmitter during nerve conduction by binding to specific G-protein-coupled receptors.

Desmopressin acetate is a synthetic replacement for vasopressin, which reduces urine production. Medical use of Desmopressin acetate includes: (a) bed wetting; (b) diabetes insipidus; (c) nighttime urination; (d) clotting disorders.

Tolvaptan (OPC-41061) is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia.

Pneumadin, rat (PNM) exerts a marked antidiuretic effect in animals has a functional AVP system. Pneumadin, rat (PNM) is a decapeptide, which possesses a potent stimulating effect on arginine-vasopressin (AVP) release.

Felypressin acetate (PLV-2) is an agonist of vasopressin 1 and acts on all arginine vasopressin receptors 1AS. Felypressin acetate can be used in dental procedures.

YM 471 is a non-peptide arginine vasopressin (AVP) V1A and V2 receptor antagonist with oral activity.

YM-430 is a β1 adrenergic receptor antagonist and a calcium channel antagonist. YM430 could be both an antianginal and antihypertensive agent. YM430 (10(-8)-10(-6) M) inhibited 3,4-diaminopyridine-induced rhythmic contractions with an IC50 value of 59.2 n

SKF 100398, also known as d(CH2)5Tyr(Et)VAVP, is a particular analog of arginine vasopressin (AVP). It acts as a specific antagonist, specifically targeting the antidiuretic effect caused by both exogenous and endogenous AVP.

Fuscoside (OPC-21268) is a non-peptide arginine vasopressin (AVP) receptor VI antagonist with an IC50 value of 0.4 μM[2].

Desmopressin acetate (16679-58-6 free base) (DDAVP) is the synthetic analog of the antidiuretic hormone arginine vasopressin. Vasopressin Receptor The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin acetate (16679-58-6 free base) works by limiting the amount of water that is eliminated in the urine. Desmopressin acetate (16679-58-6 free base) binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates the release of von Willebrand factor from endothelial cells by acting on the V2 receptor.

Mozavaptan (OPC-31260) is a competitive antagonist of vasopressin receptors, targeting both V1 and V2 receptors, with IC50 values of 1.2 μM and 14 nM, respectively.

JTP-4819 is a potent and selective prolyl endopeptidase (PEP) inhibitor with potential for treating Alzheimer's disease. At nanomolar concentrations, it inhibited the degradation of substance P, arginine-vasopressin, and thyrotropin-releasing hormone by PEP in supernatants of the rat cerebral cortex and hippocampus. Repeated administration of JTP-4819 reversed the aging-induced decrease in brain substance P-like and thyrotropin-releasing hormone-like immunoreactivity, suggesting it may improve the imbalance of peptidergic neuronal systems that develops with senescence by inhibiting PEP activity. Additionally, JTP-4819 increased acetylcholine release from the frontal cortex and hippocampus, regions closely associated with memory, in both young and aged rats.

Vasopressin acetate is a peptide hormone with vasoconstrictive and antidiuretic activities that binds to the vascular arginine vasopressin receptor, V1, with Kd values of 1.31 and 1.44 nM in A7r5 rat aortic smooth muscle cells and neonatal rat cardiomyocy

[8-L-arginine] deaminovasopressin (dAVP) is a vasopressin analog [1].

Dp[Tyr(Me)2,Arg8]-Vasopressin is a non-selective antagonist of the peptide arginine vasopressin V1b receptor [1].

[Pmp1,Tyr(OEt)2] AVP, a linear analog of the cyclic arginine vasopressin (AVP) antagonist, retains the antagonistic properties of its parent compound while featuring modified phenylalanine (Pmp) and diethyltyrosine (Tyr(OEt)2) components.

[Deamino-Pen1,Val4,D-Arg8]-vasopressin (AVP-A) is an antagonist of arginine-vasopressin (AVP) that effectively reduces plasma aldosterone concentration in rats and is used to study the growth and steroidogenic capacity of the rat adrenal zona glomerulosa [1].

Endolide F (Compound 2) is a proline-containing lactone that serves as a moderate antagonist of the arginine vasopressin V1A receptor.

Peptide pva, encoded by an RNA, is complementary to arginine vasopressin mRNA.

Salusin-β, an endogenous bioactive peptide, exhibits significant hemodynamic and mitotic activities. It can stimulate the proliferation of quiescent vascular smooth muscle cells (VSMCs) and fibroblasts, leading to a rapid and marked decrease in blood pressure and heart rate. Additionally, in rat models, Salusin-β stimulates the pituitary release of arginine vasopressin. This positions Salusin-β as a valuable compound in cardiovascular disease research.

Vasopressin V2 receptor antagonist 2 (Compound 33) is an arginine vasopressin V2 receptor (V2R) antagonist with a Ki of 6.2 nM. It effectively reduces cAMP levels, thereby inhibiting the growth of renal cysts.